JBS USA, LLC : JBS Names Former U.S. Department of Agriculture Deputy Under Secretary for Food Safety as Global Head of Food Safety and Quality Assurance
GREELEY, Colo., Aug. 03, 2017 (GLOBE NEWSWIRE) -- As part of the company's effort to serve as the worldwide leader in high-quality, innovative protein and value-added food products, JBS today announced the appointment of Alfred "Al" Almanza to the role of Global Head of Food Safety and Quality Assurance.
Almanza will join the JBS Global leadership team, reporting directly to JBS Global President of Operations, Gilberto Tomazoni. Based in Greeley, Colo., he will lead the company's global food safety efforts, ensuring that JBS operations around the world implement the highest food safety, quality control and risk management systems, while maintaining and expanding access to global export markets. JBS is the worldwide leader in protein exports, serving more than 300,000 customers in more than 150 nations.
Prior to joining JBS, Almanza spent nearly 40 years with the U.S. Department of Agriculture, Food Safety and Inspection Service (USDA, FSIS). He began his career with USDA as a food safety inspector in a small plant in Dalhart, Texas, eventually rising from this entry-level position to serve as Deputy Under Secretary for Food Safety under Secretary of Agriculture Thomas J. Vilsack, from September 2014 to December 2016. For the past 10 years, he has served as the Administrator of FSIS, leading USDA's science-based food safety modernization efforts, regulatory strategies and public health efforts to prevent foodborne illness.
"We are delighted to bring Al's expertise and passion for food safety, quality and public health to the JBS team," Tomazoni said. "During his long and storied career at FSIS, Al earned the respect and admiration of his peers for his team-based management approach and his willingness to partner with both industry and public health organizations to ensure the provision of safe, quality food to consumers. JBS is privileged to have someone of Al's caliber join our company."
Almanza is globally recognized as an expert on food safety, risk management, the development of modern inspection systems, and international sanitary standards that govern market access for meat and poultry products. During his time at FSIS, he held several leadership positions, including Labor Management specialist, District Manager of the Agency's Dallas District Office, and ultimately Administrator of FSIS, where he led a team of more than 7,000 FSIS field employees.
"I am excited to start this new chapter of my career as a part of the JBS Global Team," Almanza said. "It was an honor to serve the public as a member of the USDA team and help uphold its mission to protect public health for nearly four decades. I now join a team that shares my commitment to food safety and feeding the world in a safe, sustainable way. I look forward to helping JBS maintain the highest food safety levels in the industry, and putting in place best-in-class benchmarks and safeguards to ensure that our products continue to exceed all industry standards."
JBS is the leading animal protein producer in the world and the second-largest food company in the world, with production platforms in South America, North America, Europe and Oceania. Founded in 1953, JBS has more than 235,000 team members worldwide, more than 300 production units, export customers in more than 150 countries, and annual revenues of more than $50 billion. JBS processes, prepares, packages and delivers fresh, further-processed and value-added beef, pork, lamb and poultry products for sale to more than 300,000 customers in more than 150 countries on six continents.
Cameron Bruett, JBS Corporate Affairs
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: JBS USA, LLC via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste pressmeddelandena från NASDAQ OMX
XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer18.10.2017 16:53 | Pressmeddelande
AUSTIN, Texas, Oct. 18, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today enrollment of the first patient into a Phase I single arm study evaluating the maximum tolerated dose of Onivyde® (Irinotecan liposome injection) and 5-fluorouracil/folinic acid in combination with MABp1 in a cohort of patients with advanced pancreatic adenocarcinoma and cachexia. The patient has begun treatment at Cedars-Sinai Medical Center under the care of Dr. Andrew Hendifar, the Study's Principle Investigator, Medical Oncology lead for the Gastrointestinal Disease Research Group and Co-Director of Pancreas Oncology at Cedars-Sinai. A total of 16 patients are expected to be enrolled in the study. Dr. Hendifar commented, "We are excited to enroll our first patient in this novel combinatorial therapy for the treatment of advanced pancreatic cancer and cachexia. This is the first attempt to add an anti-inflammatory therapy to standard chemotherapy in an effort to improve the performanc
Nasdaq and SGX Establish Collaborative Listings Agreement18.10.2017 15:42 | Pressmeddelande
NEW YORK and SINGAPORE, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Nasdaq Inc. (Nasdaq:NDAQ) and Singapore Exchange (SGX) today announced the signing of a collaborative agreement in a move to leverage their strengths as two of the leading listings venues in the U.S. and Asia respectively. The new agreement seeks to enhance the channels available for companies to access capital market funding and enhance their corporate profile in both markets. As part of this agreement, Nasdaq and SGX -- who also share a successful, long-term market technology relationship -- are currently exploring the demand among corporates for a concurrent or sequential listing on both exchanges. Nasdaq and SGX are committed to supporting companies that are interested in pursuing this route. "The business landscape today is borderless," said Loh Boon Chye, CEO, SGX. "Fast-growing Asian companies looking to tap the capital markets can choose to list on SGX on Asian home ground, and embark on a listing on Nasdaq
Momentum Group acquires remaining 70 percent of Knut Sehlins Industrivaruhus in Örnsköldsvik18.10.2017 15:00 | Pressmeddelande
TOOLS Sweden (part of Momentum Group) has owned 30 percent of the shares in Knut Sehlins Industrivaruhus AB ("Sehlins") in Örnsköldsvik, Sweden since 2007. Today, TOOLS acquired the remaining 70 percent of the shares in Sehlins, which thus becomes a wholly owned subsidiary. Sehlins generates annual revenue of approximately MSEK 40 and has 14 employees. Sehlins is one of the leading industrial resellers in Örnsköldsvik, an attractive and important market with a number of successful industrial companies. The aim of the acquisition for TOOLS is to continue developing Sehlins as a wholly owned business with a focus on delivering optimal service for existing and potential customers in the local market. Sehlins has been part of TOOLS since the chain was formed in 2003. Closing takes place in October 2017. The acquisition is expected to have a marginal impact on Momentum Group's earnings per share during the current financial year. Stockholm, 18 October 2017
Momentum Group förvärvar resterande 70 procent av Knut Sehlins Industrivaruhus i Örnsköldsvik18.10.2017 15:00 | Pressmeddelande
TOOLS Sverige (inom Momentum Group-koncernen) är sedan 2007 delägare med 30 procent av aktierna i Knut Sehlins Industrivaruhus AB ("Sehlins") i Örnsköldsvik. TOOLS har idag förvärvat resterande 70 procent av aktierna i Sehlins, vilket härigenom blir ett helägt dotterbolag. Sehlins omsätter cirka 40 MSEK per år och har 14 anställda. Sehlins är en av de ledande industriåterförsäljarna i Örnsköldsvik, en intressant och viktig marknad med ett antal framgångsrika industriföretag. Syftet med TOOLS förvärv är att fortsätta utveckla Sehlins som en helägd verksamhet med fokus på att serva nuvarande och potentiella kunder på den lokala marknaden på bästa sätt. Sehlins har varit en del av TOOLS sedan starten av kedjan 2003. Tillträde sker i oktober 2017. Förvärvet bedöms ha en marginell påverkan på Momentum Groups resultat per aktie under innevarande räkenskapsår. Stockholm den 18 oktober 2017 Momentum Group AB (publ) För ytterligare inf
Colliers International Expands in Washington, D.C.18.10.2017 14:30 | Pressmeddelande
Acquisition of Beltway Real Estate Services Firm Strengthens Ongoing Commitment to the Region TORONTO and WASHINGTON, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Leading global commercial real estate services firm Colliers International Group Inc. (NASDAQ:CIGI)(TSX:CIGI) announced today the acquisition of leading tenant representation advisory firm Serten Advisors. With its office in Tysons Corner, the firm serves global, national, and regional clients with a highly skilled and experienced team of professionals that have more than 100 years of combined experience. "This strategic acquisition positions Colliers to gain additional market share and win new business in the vibrant and competitive Suburban DC markets," said Marty Pupil, Colliers International President | U.S. Brokerage. "Adding Steve and Paul and the rest of their talented leadership team to our existing group of professionals in the region will further position Colliers as the commercial real estate services firm of
InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC18.10.2017 14:00 | Pressmeddelande
InSphero AG / InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. New 3D InSight(TM) Human Liver Fibrosis Model represents a powerful tool for screening efficacy and safety of anti-fibrotic drugs in vitro. Schlieren, Switzerland, Oct. 18, 2017 (GLOBE NEWSWIRE) -- InSphero AG, the leading supplier of assay-ready 3D cell culture models for accelerating drug discovery and development, will present data characterizing and demonstrating the utility of its new 3D InSight(TM) Human Liver Fibrosis Model for screening efficacy of anti-fibrotic drugs. The findings will be presented at oral and poster presentations this Friday at the annual meeting of the American Association for the Study of Liver Disease (AASLD) Conference in Washington, DC. Anti-fibrotic therapi
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum